Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · February 24, 2022

Impact of Immunological Tests to Predict Relapse of Bullous Pemphigoid After Treatment Cessation

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: a French multicenter retrospective study
J Am Acad Dermatol 2022 Jan 25;[EPub Ahead of Print], G Battesti, C Garcia, M Viguier, V Marchal, M Castel, P Joly, AP Ledard, MP Konstantinou, V Seta, N Cordel, S Duvert-Lehembre, E Tancrède-Bohin, T Belmondo, S Ingen-Housz-Oro, M d'Incan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading